We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MIT.WS
12301
DELISTED
Mason Industrial Technology, Inc. Redeemable warrants, exercisable for one share of Class A common stock for $11.50 per share
MIT.WS
$21K ﹤0.01%
149,121
SBII.WS
12302
DELISTED
Sandbridge X2 Corp. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
SBII.WS
$21K ﹤0.01%
264,688
-10,784
-4% -$2.73K
CLPS icon
12303
CLPS Inc
CLPS
$25.8M
$20K ﹤0.01%
+12,544
New +$22.4K
LRMR icon
12304
CALL
Larimar Therapeutics
LRMR
$453M
$20K ﹤0.01%
10,200
-7,600
-43% -$22.5K
LVO icon
12305
CALL
LiveOne
LVO
$57.2M
$20K ﹤0.01%
+2,280
New +$18.7K
LXEH
12306
Lixiang Education Holding
LXEH
$3.39M
$20K ﹤0.01%
+51
New +$33K
RMTI icon
12307
Rockwell Medical
RMTI
$29.2M
$20K ﹤0.01%
1,532
+1,357
+775% +$35.9K
SLNO
12308
CALL
DELISTED
Soleno Therapeutics
SLNO
$20K ﹤0.01%
7,340
-4,987
-40% -$13.8K
SCNX
12309
Scienture Holdings
SCNX
$18.8M
$20K ﹤0.01%
880
-332
-27% -$8.37K
NVACW
12310
DELISTED
NorthView Acquisition Corporation Warrant
NVACW
$20K ﹤0.01%
176,952
-3,599
-2% -$548
CNGLW
12311
DELISTED
Canna-Global Acquisition Corp Warrant
CNGLW
$20K ﹤0.01%
252,300
TRVN
12312
PUT
DELISTED
Trevena, Inc.
TRVN
$20K ﹤0.01%
77
-1
-1% -$220
SCTL
12313
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$20K ﹤0.01%
25,478
-20,063
-44% -$21.6K
DMS
12314
DELISTED
Digital Media Solutions, Inc.
DMS
$20K ﹤0.01%
+1,171
New +$39.6K
APTO
12315
DELISTED
Aptose Biosciences, Inc.
APTO
$20K ﹤0.01%
60
+33
+122% +$15.8K
LVRAW
12316
DELISTED
Levere Holdings Corp. Warrant
LVRAW
$20K ﹤0.01%
250,200
-98
-0% -$19
ATHX
12317
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$20K ﹤0.01%
3,136
-2,492
-44% -$27.6K
ZNB
12318
Zeta Network Group
ZNB
$2.02M
0
FRMM
12319
PUT
Forum Markets
FRMM
$80.4M
$19K ﹤0.01%
6
-4
-40% -$22.9K
BTCS icon
12320
BTCS Inc
BTCS
$55.7M
$19K ﹤0.01%
+12,860
New +$35.8K
DSS icon
12321
DSS Inc
DSS
$5.68M
$19K ﹤0.01%
+2,856
New +$22.7K
GYRE icon
12322
PUT
Gyre Therapeutics
GYRE
$708M
$19K ﹤0.01%
+1,400
New +$9.3K
NEPH icon
12323
Nephros
NEPH
$50.2M
$19K ﹤0.01%
+12,123
New +$32.7K
NRXP icon
12324
PUT
NRX Pharmaceuticals
NRXP
$140M
$19K ﹤0.01%
3,210
-4,290
-57% -$56.4K
SNTG icon
12325
Sentage Holdings
SNTG
$5.55M
$19K ﹤0.01%
6,394
+2,873
+82% +$10.2K

Similar funds

Ken Griffin's Q2 2022 Portfolio in Review

As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.